393 related articles for article (PubMed ID: 29859368)
1. A dual-targeting reconstituted high density lipoprotein leveraging the synergy of sorafenib and antimiRNA21 for enhanced hepatocellular carcinoma therapy.
Li M; Su Y; Zhang F; Chen K; Xu X; Xu L; Zhou J; Wang W
Acta Biomater; 2018 Jul; 75():413-426. PubMed ID: 29859368
[TBL] [Abstract][Full Text] [Related]
2. Enhancing anti-tumor efficiency in hepatocellular carcinoma through the autophagy inhibition by miR-375/sorafenib in lipid-coated calcium carbonate nanoparticles.
Zhao P; Li M; Wang Y; Chen Y; He C; Zhang X; Yang T; Lu Y; You J; Lee RJ; Xiang G
Acta Biomater; 2018 May; 72():248-255. PubMed ID: 29555460
[TBL] [Abstract][Full Text] [Related]
3. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
[TBL] [Abstract][Full Text] [Related]
4. Reconstituted high density lipoprotein mediated targeted co-delivery of HZ08 and paclitaxel enhances the efficacy of paclitaxel in multidrug-resistant MCF-7 breast cancer cells.
Zhang F; Wang X; Xu X; Li M; Zhou J; Wang W
Eur J Pharm Sci; 2016 Sep; 92():11-21. PubMed ID: 27343697
[TBL] [Abstract][Full Text] [Related]
5. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
[TBL] [Abstract][Full Text] [Related]
6. CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1.
Xu J; Ji L; Liang Y; Wan Z; Zheng W; Song X; Gorshkov K; Sun Q; Lin H; Zheng X; Chen J; Jin RA; Liang X; Cai X
Signal Transduct Target Ther; 2020 Dec; 5(1):298. PubMed ID: 33361760
[TBL] [Abstract][Full Text] [Related]
7. Biomimetic HDL nanoparticle mediated tumor targeted delivery of indocyanine green for enhanced photodynamic therapy.
Wang Y; Wang C; Ding Y; Li J; Li M; Liang X; Zhou J; Wang W
Colloids Surf B Biointerfaces; 2016 Dec; 148():533-540. PubMed ID: 27690242
[TBL] [Abstract][Full Text] [Related]
8. Low-density lipoprotein decorated silica nanoparticles co-delivering sorafenib and doxorubicin for effective treatment of hepatocellular carcinoma.
Ye J; Zhang R; Chai W; Du X
Drug Deliv; 2018 Nov; 25(1):2007-2014. PubMed ID: 30799656
[TBL] [Abstract][Full Text] [Related]
9. RNA m
Lin Z; Niu Y; Wan A; Chen D; Liang H; Chen X; Sun L; Zhan S; Chen L; Cheng C; Zhang X; Bu X; He W; Wan G
EMBO J; 2020 Jun; 39(12):e103181. PubMed ID: 32368828
[TBL] [Abstract][Full Text] [Related]
10. Gold nanoparticles-loaded anti-miR221 enhances antitumor effect of sorafenib in hepatocellular carcinoma cells.
Cai H; Yang Y; Peng F; Liu Y; Fu X; Ji B
Int J Med Sci; 2019; 16(12):1541-1548. PubMed ID: 31839741
[No Abstract] [Full Text] [Related]
11. Direct cytosolic siRNA delivery by reconstituted high density lipoprotein for target-specific therapy of tumor angiogenesis.
Ding Y; Wang Y; Zhou J; Gu X; Wang W; Liu C; Bao X; Wang C; Li Y; Zhang Q
Biomaterials; 2014 Aug; 35(25):7214-27. PubMed ID: 24875759
[TBL] [Abstract][Full Text] [Related]
12. CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer.
Gao DY; Lin TsT; Sung YC; Liu YC; Chiang WH; Chang CC; Liu JY; Chen Y
Biomaterials; 2015 Oct; 67():194-203. PubMed ID: 26218745
[TBL] [Abstract][Full Text] [Related]
13. The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma.
Pollutri D; Patrizi C; Marinelli S; Giovannini C; Trombetta E; Giannone FA; Baldassarre M; Quarta S; Vandewynckel YP; Vandierendonck A; Van Vlierberghe H; Porretti L; Negrini M; Bolondi L; Gramantieri L; Fornari F
Cell Death Dis; 2018 Jan; 9(1):4. PubMed ID: 29305580
[TBL] [Abstract][Full Text] [Related]
14. Co-administration of combretastatin A4 nanoparticles and sorafenib for systemic therapy of hepatocellular carcinoma.
Wang Y; Yu H; Zhang D; Wang G; Song W; Liu Y; Ma S; Tang Z; Liu Z; Sakurai K; Chen X
Acta Biomater; 2019 Jul; 92():229-240. PubMed ID: 31100462
[TBL] [Abstract][Full Text] [Related]
15. A biomimetic nanovector-mediated targeted cholesterol-conjugated siRNA delivery for tumor gene therapy.
Ding Y; Wang W; Feng M; Wang Y; Zhou J; Ding X; Zhou X; Liu C; Wang R; Zhang Q
Biomaterials; 2012 Dec; 33(34):8893-905. PubMed ID: 22979990
[TBL] [Abstract][Full Text] [Related]
16. TARBP2-mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma.
Lai HH; Li CW; Hong CC; Sun HY; Chiu CF; Ou DL; Chen PS
Mol Oncol; 2019 Apr; 13(4):928-945. PubMed ID: 30657254
[TBL] [Abstract][Full Text] [Related]
17. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
[TBL] [Abstract][Full Text] [Related]
18. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
[TBL] [Abstract][Full Text] [Related]
19. Resistance of hepatocellular carcinoma to sorafenib can be overcome with co-delivery of PI3K/mTOR inhibitor BEZ235 and sorafenib in nanoparticles.
Wu B; Li A; Zhang Y; Liu X; Zhou S; Gan H; Cai S; Liang Y; Tang X
Expert Opin Drug Deliv; 2020 Apr; 17(4):573-587. PubMed ID: 32056461
[No Abstract] [Full Text] [Related]
20. Enhanced delivery of sorafenib with anti-GPC3 antibody-conjugated TPGS-b-PCL/Pluronic P123 polymeric nanoparticles for targeted therapy of hepatocellular carcinoma.
Gan H; Chen L; Sui X; Wu B; Zou S; Li A; Zhang Y; Liu X; Wang D; Cai S; Liu X; Liang Y; Tang X
Mater Sci Eng C Mater Biol Appl; 2018 Oct; 91():395-403. PubMed ID: 30033270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
